ADMA Biologics Inc vs iShares MSCI France ETF — how do they compare? ADMA Biologics Inc trades at $9.89 (market cap $2.22B), while iShares MSCI France ETF trades at $47.51. The key difference: iShares MSCI France ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | EWQ | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $48.35 |
52-Week Low | $7.60 | $41.68 |
Enterprise Value | $2.29B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
EWQ, the iShares MSCI France ETF, trades at $47.505, down 0.51% on the day, with a bullish technical signal driven by moving averages. The ETF focuses on French equities, particularly industrials, and offers a dividend scheduled for June 2026. Recent news highlights ECB rate decisions and French tech investments, influencing sentiment.
The outlook for EWQ is supported by bullish technicals and positive analyst views on French stocks, but risks include ECB policy shifts and geopolitical tensions. Investors may find opportunity in Europe's cyclical recovery, though volatility from energy prices and economic data poses challenges.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →